Journals / European Journal of Therapeutics / 2020 / Cilt: 26 - Sayı: 3

Do Patients with Differentiated Thyroid Cancer Face the Risk of Hyponatremia at the Expense of Preparation for Radioactive Iodine Treatment?

Pages
233–237
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no significant correlation between serum Na levels andage, serum TSH, or the hormone levels.Conclusion: In conclusion, preparation for RAI treatment with LT4 withdrawal and or a low-iodine diet is not a common etiologicalfactor for the development of hyponatremia in patients with DTC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Differentiated thyroid cancer (DTC) is the most common endocrine cancer.
📊
Key Findings & Data:The main therapeutic strategies are surgeryand radioactive iodine (RAI) treatment in selected intermediate- and high-risk patients.
💡
Conclusion & Impact:There was no significant correlation between serum Na levels andage, serum TSH, or the hormone levels.Conclusion: In conclusion, preparation for RAI treatment with LT4 withdrawal and or a low-iodine diet is not a common etiologicalfactor for the development of hyponatremia in patients with DTC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Differentiated thyroid cancer (DTC) is the most common endocrine cancer. The main therapeutic strategies are surgeryand radioactive iodine (RAI) treatment in selected intermediate- and high-risk patients. Hyponatremia is the most frequent formof electrolyte imbalance and few studies have assessed the frequency and clinical impact of hyponatremia in patients with thyroid cancer. In this study, we aimed to determine the prevalence and severity of hypo¬natremia among hypothyroid patients inthe peri-ablation period. The secondary objective was to assess the correlation between Sodium (Na) level and hypothyroidismseverity, age, and RAI dosage.Methods: A total of 51 patients with DTC who were referred to our Nuclear Medicine Department for RAI ablation/treatment wereenrolled. Serum Na, thyroid-stimulating hormone (TSH), and free triiodothyronine and thyroxine levels were measured three timesduring the study (under LT4 suppression, when the patient was hypothyroid before and after receiving RAI). Baseline, pre-, and postRAI mean serum Na and other hormonal parameters were compared. The number of patients with hyponatremia and possible relatedsymptoms were noted. Correlation of serum Na levels with age, RAI dosage, and hypothyroidism severity was determined.Results: The number of patients with hyponatremia did not differ significantly in the baseline, pre-, and post-RAI periods. None ofthe patients experienced moderate-to-severe hyponatremia. There was no significant correlation between serum Na levels andage, serum TSH, or the hormone levels.Conclusion: In conclusion, preparation for RAI treatment with LT4 withdrawal and or a low-iodine diet is not a common etiologicalfactor for the development of hyponatremia in patients with DTC.

🔖

Cite This Article

ÖZDEMİR, E., DELAY, N. B., POLAT, Ş. B. (2022). Do Patients with Differentiated Thyroid Cancer Face the Risk of Hyponatremia at the Expense of Preparation for Radioactive Iodine Treatment?. European Journal of Therapeutics, Cilt: 26 - Sayı: 3, 233–237. https://ajindex.com/articles/512181

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016
  2. [Crossref] 2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016
  3. [Crossref] 3. Orosco RK, Hussain T, Noel JE, Chang DC, Dosiou C, Mittra E, et al. Radioactive iodine in differentiated thyroid cancer: a national database perspective. Endocr Relat Cancer 2019
  4. [Crossref] 4. Twining CL, Lupo MA, Tuttle RM. Implementing Key Changes in the American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types. Endocr Pract 2018
  5. [Crossref] 5. Niri T, Horie I, Ando T, Kawahara H, Ueda M, Eto M, et al. Renal Function and Plasma Renin Activity as Potential Factors Causing Hyperkalemia in Patients with Thyroid Carcinoma Undergoing Thyroid Hormone Withdrawal for Radioactive Iodine Therapy. Endocr Pract 2020
  6. [Crossref] 6. Vannucci L, Parenti G, Simontacchi G, Rastrelli G, Giuliani C, Ognibene A, et al. Hypothyroidism and hyponatremia: data from a series of patients with iatrogenic acute hypothyroidism undergoing radioactive iodine therapy after total thyroidectomy for thyroid cancer. J Endocrinol Invest 2017
  7. [Crossref] 7. Nozu T, Yoshida Y, Ohira M, Okumura T. Severe hyponatremia in association with I(131) therapy in a patient with metastatic thyroid cancer. Intern Med 2011
  8. [Crossref] 8. Kim J, Cho SG, Kang SR, Kwon SY, Cho DH, Cho JS, et al. Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients. Medicine (Baltimore) 2017
  9. e6004. [Crossref] 9. Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, Consensus, and Collaboration in the Use of (131) I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 2019
  10. [Crossref] 10. Tang CYL, Thang SP, Zaheer S, Kwan CK, Ng DC. Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population. Endocrine 202